The promising potential role of ketones in inflammatory dermatologic disease: a new frontier in treatment research

References

• Kumar V. Cellular Repair and Inflammation. Robbins and Cotran Pathologic Basis of Disease, 9th ed. Philadelphia: Elsevier Saunders, 2014.
   Google Scholar
• Dashti HM, Mathew TC, Hussein T, et al. Long-term effects of a ketogenic diet in obese patients. Exp Clin Cardiol. 2014;9:200–5.
   Google Scholar
• Mandel A, Ballew M, Pina-Garza JE, et al. Medical costs are reduced when children with intractable epilepsy are successfully treated with the ketogenic diet. J Am Diet Assoc. 2002;102:396–8.
   PubMedGoogle Scholar
• Rho JM, Rogawski MA. The ketogenic diet: stoking the powerhouse of the cell. Epilepsy Curr. 2007;7:58–60.
   PubMedGoogle Scholar
• Masino SA, Kawamura M, Wasser CD, et al. Adenosine, ketogenic diet and epilepsy: the emerging therapeutic relationship between metabolism and brain activity. Curr Neuropharmacol. 2009;7:257–68.
   PubMed Web of Science ®Google Scholar
• Gardner CD, Kiazand A, Alhassan S, et al. Comparison of the Atkins, Zone, Ornish, and LEARN diets for change in weight and related risk factors among overweight premenopausal women: the A TO Z weight loss study: a randomized trial. JAMA. 2007;297:969–77.
   PubMed Web of Science ®Google Scholar
• Zajac A, Poprzecki S, Maszczyk A, et al. The effects of a ketogenic diet on exercise metabolism and physical performance in off-road cyclists. Nutrients. 2014;6:2493–508.
   PubMed Web of Science ®Google Scholar
• Poff AM, Ari C, Seyfried TN, et al. The ketogenic diet and hyperbaric oxygen therapy prolong survival in mice with systemic metastatic cancer. PLoS One. 2013;8:65522.
   PubMed Web of Science ®Google Scholar
• Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med. 2015;21:263–9.
   PubMed Web of Science ®Google Scholar
• Schachter S, Kossoff E, Sirven J, Epilepsy Foundation. “Ketogenic Diet.” Epilepsy. 2013. Available from http://www.epilepsy.com/learn/treating-seizures-and-epilepsy/dietary-therapies/ketogenic-diet. Accessed January 16, 2016.
   Google Scholar
• Veech RL, Chance B, Kashiwaya Y, et al. Ketone bodies, potential therapeutic uses. IUBMB Life. 2001;51:241–7.
   PubMed Web of Science ®Google Scholar
• Taubes G. Good Calories, Bad Calories. New York: Random House, 2008.
   Google Scholar
• Hartman A, Vining E. Clinical aspects of the ketogenic diet. Epilepsia. 2007;48:31–42.
   PubMed Web of Science ®Google Scholar
• Freeman J, Kossoff E, Hartman A. The ketogenic diet: one decade later. Pediatrics. 2007;119:535–43.
   PubMed Web of Science ®Google Scholar
• Menu P, Vince JE. The NLRP3 Inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol. 2011;166:1–15.
   PubMed Web of Science ®Google Scholar
• Miyamae T. Cryopyrin-associated periodic syndromes: diagnosis and management. Paediatr Drugs. 2012;14:109
   PubMed Web of Science ®Google Scholar
• Rigante D, Ansuini V, Bertoni B, et al. Treatment with anakinra in the hyperimmunoglobulinemia D/periodic fever syndrome. Rheumatol Int. 2006;27:97–100.
   PubMed Web of Science ®Google Scholar
• Simon A, Bodar EJ, van der Hilst JC, et al. Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med. 2004;117:208–10.
   PubMed Web of Science ®Google Scholar
• Kalliolias GD, Liossis SN. The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still’s disease and systemic-onset juvenile idiopathic arthritis. Exp Opin Invest Drugs. 2008;17:349–59.
   PubMed Web of Science ®Google Scholar
• Pizzirani C, Falzoni S, Govoni M, et al. Dysfunctional inflammasome in Schnitzler's syndrome. Rheumatology (Oxford). 2009;48:1304–8.
   PubMed Web of Science ®Google Scholar
• Delluc A, Limal N, Puéchal X, et al. Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome. Ann Rheum Dis. 2008;67:278–9.
   PubMed Web of Science ®Google Scholar
• Botsios C, Sfriso P, Furlan A, et al. Resistant Behçet disease responsive to anakinra. Ann Intern Med. 2008;149:284–6.
   PubMed Web of Science ®Google Scholar
• Sundy JS. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol. 2010;22:188–93.
   PubMed Web of Science ®Google Scholar
• Onozaki K, Matsushima K, Aggarwal BB, et al. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol. 1985;135:3962–8.
   PubMed Web of Science ®Google Scholar
• Bryan N, Dorfleutner A, Rojanasakul Y, et al. Activation of inflammasomes requires intracellular redistribution of the apoptotic speck-like protein containing a caspase recruitment domain. J Immunol. 2009;182:3173–82.
   PubMed Web of Science ®Google Scholar
• Hiramoto K, Kobayashi H, Yamate Y, et al. Intercellular pathway through hyaluronic acid in UBV-induced inflammation. Exp Dermatol. 2012;21:911–4.
   PubMed Web of Science ®Google Scholar
• Beer H, Emmanuel C, French L. The inflammasomes in autoinflammatory diseases with skin involvement. J Invest Dermatol. 2014;134:1805–10.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Muneer KM, Tamimi IA, et al. Thymoquinone suppresses metastasis of melanoma cells by inhibition of NLRP3 inflammasome toxicology applications in. Pharmacology. 2013;270:70–6.
   Web of Science ®Google Scholar
• Gross CJ, Gross O. The NLRP3 inflammasome admits defeat. Trends Immunol. 2015;36:323–4.
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LA. Inflammasome inhibition: putting out the fire. Cell Metab. 2015;721:513–4.
   PubMed Web of Science ®Google Scholar
• Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015;21:248–55.
   PubMed Web of Science ®Google Scholar
• Shao BZ, Xu ZQ, Han BX, et al. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262
   PubMed Web of Science ®Google Scholar
• Salzano S. Linkage of inflammation and oxidative stress via release of glutathionylated peroxiredoxin-2, which acts as a danger signal. Proc Natl Acad Sci USA. 2012;33:12157–62.
   Google Scholar
• Trenam CW, Blake DR, Morris CJ. Skin inflammation: reactive oxygen species and the role of iron. J Invest Dermatol. 1992;99:675–82.
   PubMed Web of Science ®Google Scholar
• Okayama Y. Oxidative stress in allergic and inflammatory skin diseases. Curr Drug Targets Inflamm Allergy. 2005;4:517–9.
   PubMedGoogle Scholar
• Cerutti P, Shah G, Peskin A, et al. Oxidant carcinogenesis and antioxidant defense. Ann NY Acad Sci. 1992;663:158–66.
   PubMed Web of Science ®Google Scholar
• Athar M. Oxidative stress and experimental carcinogenesis. Indian J Exp Biol. 2002;40:656–67.
   PubMedGoogle Scholar
• Nishigori C, Hattori Y, Toyokuni S. Role of reactive oxygen species in skin carcinogenesis. Antioxid Redox Signal. 2004;6:561–70.
   PubMed Web of Science ®Google Scholar
• Allhorn M, Lundqvist K, Schmidtchen A, et al. Heme-scavenging role of alpha1-microglobulin in chronic ulcers. J Invest Dermatol. 2003;121:640–6.
   PubMed Web of Science ®Google Scholar
• Anderson C, Hehr A, Robbins R, et al. Metabolic requirements for induction of contact hypersensitivity to immunotoxic polyaromatic hydrocarbons. J Immunol. 1995;155:3530–7.
   PubMed Web of Science ®Google Scholar
• Briganti S, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What's new? J Eur Acad Dermatol Venereol. 2003;17:663–9.
   PubMed Web of Science ®Google Scholar
• Milder J, Patel M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res. 2012;100:295–303.
   PubMed Web of Science ®Google Scholar
• Rhyu H, Cho S, Roh H. The effects of ketogenic diet on oxidative stress and antioxidative capacity markers of Taekwondo athletes. J Exercise Rehab. 2014;10:362–6.
   PubMedGoogle Scholar
• Milder J, Liang L, Patel M. Acute oxidative stress and systemic Nrf2 activation by the ketogenic diet. Neurobiol Dis. 2010;40:238–44.
   PubMed Web of Science ®Google Scholar
• Venugopal R. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc Natl Acad Sci USA. 1996;93:14960–5.
   PubMed Web of Science ®Google Scholar
• Hayes JD, Chanas SA, Henderson CJ, et al. The Nrf2 transcription factor contributes both to the basal expression of glutathione S-transferases in mouse liver and to their induction by the chemopreventive synthetic antioxidants, butylated hydroxyanisole and ethoxyquin. Biochem Soc Trans. 2000;28:33–41.
   PubMed Web of Science ®Google Scholar
• Solis WA, Dalton TP, Dieter MZ, et al. Glutamate-cysteine ligase modifier subunit: mouse Gclm gene structure and regulation by agents that cause oxidative stress. Biochem Pharmacol. 2000;63:1739–54.
   Web of Science ®Google Scholar
• Wang J, Doré S. Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain. 2007;130:1643–52.
   PubMed Web of Science ®Google Scholar
• Yueh MF, Tukey RH. Nrf2-Keap1 signaling pathway regulates human UGT1A1 expression in vitro and in transgenic UGT1 mice. J Biol Chem. 2007;282:8749–58.
   PubMed Web of Science ®Google Scholar
• Neumann CA, Cao J, Manevich Y. Peroxiredoxin 1 and its role in cell signaling. Cell Cycle. 2009;8:4072–8.
   PubMed Web of Science ®Google Scholar
• Soriano FX, Baxter P, Murray LM, et al. Transcriptional regulation of the AP-1 and Nrf2 target gene Sulfiredoxin. Mol Cells. 2009;27:279–82.
   PubMed Web of Science ®Google Scholar
• Jarmi T, Agarwal A. Heme oxygenase and renal disease. Curr Hypertens Rep. 2009;11:56–62.
   PubMed Web of Science ®Google Scholar
• Marwan M. Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation. Neuroscience. 2007;145:256–64.
   PubMed Web of Science ®Google Scholar
• Hay N, Sonenberg N. Upstream and downstream of mTOR genes. Genes Dev. 2004;18:1926–45.
   PubMed Web of Science ®Google Scholar
• Lee D, Hung M. All roads lead to mTOR: integrating inflammation and tumor angiogenesis. Cell Cycle. 2007;6:3011–4.
   PubMed Web of Science ®Google Scholar
• Weichart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. Nat Rev Immunol. 2015;15:599–614.
   PubMed Web of Science ®Google Scholar
• Geissler E. Skin cancer in solid organ transplant recipients: are mTOR inhibitors a game changer? Transplant Res. 2015;4:1.
   PubMed Web of Science ®Google Scholar
• Kuschal C. Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Exp Dermatol. 2012;21:2–6.
   PubMed Web of Science ®Google Scholar
• Alter M, Satzger I, Schrem H, et al. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR inhibitors in organ transplant recipients. J Dtsch Dermatol Ges. 2014;12:480–8.
   PubMed Web of Science ®Google Scholar
• McDaniel S. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia. 2011;52:7–11.
   PubMed Web of Science ®Google Scholar
• Staftsrom C, Rho J. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol. 2012;3:59.
   PubMed Web of Science ®Google Scholar